MP Advisors is a Consultancy firm with an exclusive focus on Pharmaceuticals / Biotechnology sectors in the US, Europe, India, Japan and Russia. It was operating earlier as an international affiliate of Mehta Partners LLC since 1996. Today it has a highly motivated, qualified team of PhDs, MBAs and Pharmacist who apply their domain knowledge to develop proprietary data bases, understand dynamic regulatory laws across geographies, track and analyze latest trends in drug development, clinical trials and specific diseases.
 
MP Advisors has insightful information on more than 200 pharma and Biotech companies around the globe as well as publishes reports on Key Opinion Leaders (Physician’s view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity, Novel Drug Delivery systems, Biosimilars etc.), India and Japan generic opportunities and Paragraph IV Opportunities.

Page

Hepatitis C Virus Infection

By MP Advisors | Healthcare | Oct 2013 | Page 33

Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This....

USD 1000 View Report

Rituximab biosimilar

By MP Advisors | Healthcare | Oct 2013 | Page 45

Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnsons Remicade,....

USD 2000 View Report

Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

By MP Advisors | Healthcare | Aug 2013 | Page 37

The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition....

USD 2500 View Report

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed

By MP Advisors | Healthcare | Jul 2013 | Page 14

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed....

USD 800 View Report

Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies

By MP Advisors | Healthcare | Jun 2013 | Page 123

There are more than 1400 sustained or controlled release drugs approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012,....

USD 2500 View Report